Development of a symptom distress scale

McCorkle, Ruth; Young, Katherine S.

doi:10.1097/00002820-197810000-00003

Cited by 695 publications

(446 citation statements)

References 0 publications

Supporting

Mentioning

439

Contrasting

Unclassified

Order By: Relevance

“…Although in most studies fatigue was examined as a side effect of chemotherapy [19,27], several studies did report findings similar to this study on pre-treatment fatigue. Cimprich [16] used the Symptom Distress Scale [31] to measure distress symptoms during the pretreatment period of 74 women who were newly diagnosed with breast cancer and found that 90% reported some mood disturbance, 65% reported some loss of concentration, and 77% reported fatigue defined as tiredness. All three of these types of distress are included in the definition of fatigue in this study.…”

Section: Discussionmentioning

confidence: 99%

Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer

Ancoli‐Israel

Liu

Marler

et al. 2005

Support Care Cancer

267

206

View full text Add to dashboard Cite

Goals-Previous investigations have shown that women undergoing chemotherapy for breast cancer experience both disturbed sleep and fatigue. However, most of the previous research examined women either during or after chemotherapy. This study examined sleep, fatigue, and circadian rhythms in women with breast cancer before the start of chemotherapy.Patients and methods-Eighty five women with Stages I-IIIA breast cancer who were scheduled to begin adjuvant or neo-adjuvant anthracycline-based chemotherapy participated. Each had sleep/ wake activity recorded with actigraphy for 72 consecutive hours and filled out questionnaires on sleep, fatigue, depression, and functional outcome.Main results-On average, the women slept for about 6 h a night and napped for over an hour during the day. Sleep was reported to be disturbed and fatigue levels were high. Circadian rhythms were robust, but women who were more phase-delayed reported more daily dysfunction (p<0.01). Conclusions-The data from the current study suggest that the women with breast cancer likely experience both disturbed sleep and fatigue before the beginning of chemotherapy. Although their circadian rhythms are robust, breast cancer patients with more delayed rhythms experience more daily dysfunction secondary to fatigue. These data suggest that strategies to improve disturbed sleep and to phase-advance circadian rhythms prior to initiation of chemotherapy may be beneficial in improving daily function in breast cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer

Ancoli‐Israel

Liu

Marler

et al. 2005

Support Care Cancer

267

206

View full text Add to dashboard Cite

show abstract

“…1) was introduced in 2000, 1 several multisymptom assessment scales, including the Symptom Distress Scale, 5 the Memorial Symptom Assessment Scale, 6 the Rotterdam Symptom Checklist, 7 and the Edmonton Symptom Assessment System, 8 were already in use among patients with cancer in Western countries. The MDASI, however, has several advantages over these other tools.…”

mentioning

confidence: 99%

Chinese version of the M. D. Anderson Symptom Inventory

Wang

Guo

et al. 2004

Cancer

185

View full text Add to dashboard Cite

BACKGROUNDSymptom management is an essential component of cancer treatment for patients of every culture and nationality. Symptom assessment depends on subjective reporting, mandating linguistically equivalent versions of symptom assessment scales. Because disease‐related and treatment‐related symptoms most often occur in clusters, there is a global need for a standardized multiple‐symptom assessment tool.METHODSThe authors sought to validate the Chinese version of the M. D. Anderson Symptom Inventory (MDASI‐C) by enrolling patients who had received various diagnoses of and different types of treatment for cancer (n = 249) in a cross‐sectional symptom study conducted at an urban cancer center in China.RESULTSFactor analysis identified 2 underlying constructs, general symptoms and gastrointestinal symptoms, which had Cronbach alpha coefficients of 0.86 and 0.84, respectively. These results were consistent with English‐ and Japanese‐language MDASI validation studies. Known‐group validity was supported by the MDASI‐C's ability to detect significant differences in symptom and interference levels according to Eastern Cooperative Oncology Group performance status (ECOG PS; P < 0.001) and chemotherapy status (P < 0.05). Fifty‐five percent of the study cohort had ≥ 1 symptom that was considered severe (score ≥ 7 on a 0–10 scale). ECOG PS was strongly associated with symptom burden (total interference score: R2 = 0.26; P < 0.001). Fatigue, sadness, drowsiness, and lack of appetite accounted for most of the variability in the total interference score (R2 = 0.49; P < 0.05).CONCLUSIONSThe authors demonstrated that the MDASI‐C is a valid, reliable, and concise tool for measuring symptom severity and interference with functioning in Chinese cancer patients. Cancer 2004. © 2004 American Cancer Society.

show abstract

“…Secondary endpoints included RBC transfusion requirements, adverse events (AEs), and Patient Reported Outcomes (PROs). PROs were measured using several validated tools: the Symptom Distress Scale (SDS) [18], Brief Fatigue Inventory (BFI) [19], Functional Assessment of Cancer Therapy Anemia (FACT-An) [20], and Linear Analog Self Assessment (LASA) [21]. Adverse events were reported using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.…”

Section: Methodsmentioning

confidence: 99%

A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy‐associated anemia

et al. 2015

View full text Add to dashboard Cite

Erythropoiesis‐stimulating agents (ESAs) epoetin alfa (EA) and darbepoetin alfa (DA) increase hemoglobin (Hb) levels and reduce red blood cell (RBC) transfusion requirements in patients with cancer chemotherapy‐associated anemia (CAA). Extended‐interval ESA dosing (administration less than once weekly) is common with DA, but previous studies suggested that EA might also be administered less often than weekly. In this multicenter prospective trial, 239 CAA patients with Hb <10.5 g/dL were randomized to receive EA 40,000 U subcutaneously once weekly (“40K” arm), EA 80,000 U every 3 weeks (“80K”), EA 120,000 U every 3 weeks (“120K” arm), or DA 500 mcg every 3 weeks (“DA”), for 15 weeks. The primary endpoint was the proportion of patients achieving Hb ≥ 11.5 g/dL or increment of Hb > 2.0 g/dL from baseline without transfusion. Secondary endpoints included transfusion requirements, adverse events (AEs), and patient‐reported outcomes (PROs). There were no significant differences between treatment arms in the proportion of patients achieving Hb response (68.9% for 40K, 61.7% for 80K, 65.5% for 120K, and 66.7% for DA; P > 0.41 for all comparisons) or requiring RBC transfusion, but the median Hb increment from baseline was higher in the 40K and DA arms compared to the two extended dosing EA arms, and Hb response was achieved soonest in the weekly EA arm. There were no differences in PROs or AEs. The FDA‐approved schedules tested—weekly EA 40,000 U, and every 3 week DA 500 mcg—are reasonable standards for CAA therapy. Am. J. Hematol. 90:877–881, 2015. © 2015 Wiley Periodicals, Inc.

show abstract

Development of a symptom distress scale

Cited by 695 publications

References 0 publications

Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer

Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer

Chinese version of the M. D. Anderson Symptom Inventory

A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy‐associated anemia

Contact Info

Product

Resources

About